Pyxis Oncology (PYXS) just unveiled an announcement.
Pyxis Oncology, Inc. has enriched its Board of Directors with the addition of Michael A. Metzger, deemed an independent director by Nasdaq and SEC standards. Metzger, who has no prior relationships or transactions with the company that would raise conflict of interest concerns, will serve on the Board through the 2026 annual stockholders’ meeting and contribute to the Audit and Compensation Committees. He will receive compensation as per the company’s established plan and has been granted stock options that vest over three years, enhancing his stake in the company’s future success.
Learn more about PYXS stock on TipRanks’ Stock Analysis page.
